

Aritoshi Iida · Susumu Saito · Akihiro Sekine
Yukie Kataoka · Wataru Tabei · Yusuke Nakamura

Catalog of 300 SNPs in 23 genes encoding G-protein coupled receptors

Received: 14 January 2004 / Accepted: 15 January 2004 / Published online: 20 March 2004
© The Japan Society of Human Genetics and Springer-Verlag 2004

Abstract We previously published a series of detailed maps of single nucleotide polymorphisms (SNPs) in the genomic regions of 209 gene loci encoding drug metabolizing enzymes, transporters, receptors, and other potential drug targets. In addition to the maps reported earlier, we provide here high-resolution SNP maps of 23 genes encoding G-protein coupled receptors in the Japanese population. A total of 300 SNPs were identified through screening of these loci; 83 in four adenosine receptor family genes, 45 in three adrenergic receptor family genes, 22 in three EDG receptor family genes, 29 in three melanocortin receptor family genes, 22 in two somatostatin receptor family genes, 21 in five anonymous G protein-coupled receptor family genes, and 78 in the others (*AVPR1B*, *OXTR*, and *TNFRSF1A*). We also discovered a total of 33 genetic variations of other types. Of the 300 SNPs, 132 (44%) appeared to be novel on the basis of comparisons with the dbSNP database of the National Center for Biotechnology Information (US) or with previous publications. The maps constructed in this study will serve as an additional resource for studies of complex genetic diseases and drug-response phenotypes

to be mapped by linkage-disequilibrium association analyses.

Keywords Single nucleotide polymorphism · Adenosine receptor genes · Adrenergic receptor genes · EDG receptor genes · Melanocortin receptor genes · Somatostatin receptor genes · Anonymous G protein-coupled receptor genes · Japanese population · High-density SNP map

Introduction

One of major goals in our laboratory is to establish “personalized medicine” on the basis of single nucleotide polymorphisms (SNPs) regarding responsiveness or adverse effects to drugs and susceptibility to common diseases. To achieve this aim, we have been conducting extensive screening programs to isolate SNPs in the Japanese population. Particularly, we have focused on SNP mapping in 209 genomic regions that correspond to genes involved in the metabolism of drugs and have constructed high-density SNP maps containing more than 6,500 genetic variations (Iida et al. 2001a,b,c,d,e, 2002a,b,c,d, 2003; Saito et al. 2001a,b, 2002a,b,c,d, 2003a,b; Sekine et al. 2001). Moreover, these efforts have allowed us to identify a total of five mutations that may affect the gene products, including two nonsense mutations in *CYP* genes and three frame-shift mutations (two in *CYP* genes and one in the *MGST1* gene) among Japanese healthy donors (see a review by Iida and Nakamura 2003).

G-protein coupled receptors are cell-surface proteins and are responsible for the signal transduction for a variety of extracellular chemical signals such as photons, Ca^{2+} , nucleotides, amino acids, peptides, amines, fatty derivatives, and various polypeptide ligands (see a review by Howard et al. 2001). On recognition of such ligands, these proteins mediate a variety of intracellular signals via activation of heterotrimeric G-proteins that in turn, activate various effector proteins, consequently

A. Iida (✉) · Y. Nakamura
Laboratory for Pharmacogenetics, Research Groups
of Personalized Medicine, RIKEN SNP Research Center,
c/o RIKEN Yokohama Institute, 1-7-22 Suenhiro-cho,
Tsurumi, Yokohama, Kanagawa 230-0045, Japan
E-mail: iidaari@src.riken.go.jp
Tel.: +81-45-5039599
Fax: +81-45-5039326

S. Saito
Laboratory for SNP Analysis, Research Groups
of Personalized Medicine, RIKEN SNP Research Center,
c/o Institute of Medical Science, The University of Tokyo,
Tokyo, Japan

A. Sekine · Y. Kataoka · W. Tabei
Laboratory for Genotyping, RIKEN SNP Research Center,
c/o RIKEN Yokohama Institute, Kanagawa, Japan

Y. Nakamura
Laboratory of Molecular Medicine, Human Genome Center,
Institute of Medical Science, The University of Tokyo,
Tokyo, Japan





Fig. 1 Fine-scale single nucleotide polymorphism (SNP) maps of 23 gene loci encoding G-protein coupled receptors. Exons and introns are represented by rectangles and horizontal lines, respectively. SNPs are indicated above the lines (designations correspond to the left-most column of Table 1). Genetic variations of other types, where present, are indicated below the maps. However, the complete 5' untranslated sequences and/or 3' untranslated sequences of *ADRA2B*, *EDG5*, *MC3R*, *SSTR3*, *GPR3*, and *GPR10* were yet unidentified in database we used

**Fig. 1** (continued)


**Fig. 1** (continued)

Table 1 Summary of genetic variations identified in 23 gene-encoding G-protein coupled receptors. *SNP* Single nucleotide polymorphism

Gene symbol	Accession number (genomic DNA)	Genome size	Screening region	SNP	Other type of variation	Total	Nonsynonymous substitution	Identity to dbSNP/ previous report	New SNP
<i>ADORA1</i>	AC105940.2	80.8	22.9	40	5	45	0	20	20
<i>ADORA2A</i>	AP000355.1	13.3	9.1	11	1	12	1	7	4
<i>ADORA2B</i>	AC006251.3	36	11.9	16	1	17	0	10	6
<i>ADORA3</i>	AL390195.10	9	6.3	16	0	16	1	10	6
<i>ADRA1A</i>	AC025712.4	>33.6	18.4	26	8	34	1	18	8
<i>ADRA2A</i>	AL158163.11	8.9	8.4	12	0	12	0	10	2
<i>ADRA2B</i>	AC092603.2	7.3	5.2	7	2	9	0	4	3
<i>AVPR1B</i>	AF152238.1	12	8	35	2	37	3	1	34
<i>EDG1</i>	AL109741.19	8.5	6.6	11	3	14	0	6	5
<i>EDG4</i>	AC011458.7	8.5	4.5	6	0	6	0	3	3
<i>EDG5</i>	AC011511.12	5.1	3.3	5	1	6	1	4	1
<i>MC1R</i>	AC092143.3	5.3	4.7	15	0	15	4	11	4
<i>MC3R</i>	AL139824.22	5.1	3.5	8	0	8	2	7	1
<i>MC4R</i>	AC091576.11	5	4.8	6	1	7	1	3	3
<i>OXTR</i>	AF176315.2	23	14.5	27	0	27	1	17	10
<i>SSTR1</i>	AL450109.3	10	8.5	13	2	15	0	7	6
<i>SSTR3</i>	Z82188.2	6	4.9	9	0	9	0	7	2
<i>TNFRSF1A</i>	AC006057.5	17.3	10.7	16	5	21	1	11	5
<i>GPR1</i>	AC007383.4	5.1	2.4	5	0	5	3	4	1
<i>GPR2</i>	AC027146.1	6.4	3.7	2	0	2	0	1	1
<i>GPR3</i>	AL096774.9	5	4	2	1	3	0	1	1
<i>GPR4</i>	AC011480.3	6.7	3.2	7	1	8	0	3	4
<i>GPR10</i>	AC067895.2	5.1	4.9	5	0	5	0	3	2
Total		289.4	174.4	300	33	333	19	168	132

resulting in a physiologic response for the cell (Marinissen and Gutkind 2001). G-protein coupled receptors are members of a large multigene family characterized by similar structure, which consists of seven alpha-helical transmembrane segments connected by three intracellular and three extracellular loops, an extracellular amino-terminal domain, and an intracellular carboxyl-terminal domain. So far, a large number of studies have reported genetic variations of G-protein coupled receptor gene loci and their role in etiology or predisposition of human diseases (Rana et al. 2001). G-protein coupled receptors are also considered to be good potential targets for drug development (Howard et al. 2001).

To expand the genetic basis for drug development as well as eventually to enable clinicians to predict efficacy and adverse drug reactions, we explored SNPs among 23 genes encoding G-protein coupled receptors. In this report, we provide high-resolution maps of these gene loci containing a total of 300 SNPs and 33 genetic variations of other types that we detected in DNAs from 48 Japanese volunteers.

Subjects and methods

Samples of peripheral blood were obtained with written informed consent from 48 healthy Japanese volunteers for this study. The SNP screening method described in an earlier report by Haga et al. (2002) was the principal technique applied in this study. In brief, on the basis of genomic sequences corresponding to each of the receptor genes from the GenBank database in the US National Center for Biotechnology Information (NCBI), we designed primers to amplify all selected genes in their entirety, excluding only regions that corresponded to repetitive sequences predicted by

the RepeatMasker program (<http://repeatmasker.genome.washington.edu/cgi-bin/RepeatMasker>). All gene symbols mentioned through this report are according to the nomenclature in LocusLink of NCBI.

Each polymerase chain reaction (PCR) was performed using 20 ng of a mixture of genomic DNAs from three individuals. All 16 mixed samples were amplified in the GeneAmp PCR system 9700 (PE Applied Biosystems, Foster City, Calif., USA) under the following conditions: initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 2 min, and post-extension at 72°C for 7 min. Products obtained from the PCR experiments served as templates for direct sequencing and detection of SNPs, using the fluorescent dye-terminator cycle-sequencing method. All SNPs detected by the polyphred computer program (Nickerson et al. 1997) were confirmed by sequencing both strands of each PCR product.

Results and discussion

By direct sequencing of DNA from 96 chromosomes, we screened SNPs in a total of approximately 174.4-kb genomic sequences that accounted for 60% of the 289.4-kb genomic region encompassing the loci of 23 selected genes, excluding the regions corresponding to human repetitive sequences. We identified a total of 333 variations, including 300 SNPs and 33 genetic variations of other types, and constructed a fine-scale SNP map of each locus (Fig. 1, Table 1). Detailed information for each variation identified in this study is summarized in Table 2. The overall genomic distribution of SNP was 1 in every 581 nucleotides in the 174.4-kb region that we sequenced. The overall frequencies of nucleotide substitutions in our test population were counted as 31% for A/G, 36.3% for C/T, 10% for C/G, 9.3% for T/G, 7.3%

Table 2 Characterization of 333 genetic variations in 23 gene loci corresponding to G-protein coupled receptors. *dbSNP* Database of single-nucleotide polymorphisms, *ins* insertion polymorphism, *del* deletion polymorphism

ID	Location	Exon	Position ^a	5' Flanking sequence ^b	Variation ^c	3' Flanking sequence ^b	Substitution	Identity to dbSNP/ previous report
Adenosine A1 receptor ^d	5' Flanking region							
i-ADORA1-1	Intron 2		-54	gtccccctttccccaat	C/T	atggggaaatggaggccgg	rs7518889	
i-ADORA1-2	Intron 2		79	tgttcatacttgttgat	T/G	tgcctccgttgcct		
i-ADORA1-3	Intron 2		533	tctttttacgttgtggcc	G/A	tttttttttaaatggc	rs1389793	
i-ADORA1-4	Intron 2		8422	tagggcggttttttttgg	C/A	tttttttttttttttttttt		
i-ADORA1-5	Intron 2		8094	gttttttttttttttttttt	T/C	aattttttttttttttttttt		
i-ADORA1-6	Intron 2		24377	ctggggcggtttttttttt	G/C	cettttttttttttttttttt		
i-ADORA1-7	Intron 2		26819	tttttttttttttttttttt	C/T	gaccggaaaatggccatt	rs722915	
i-ADORA1-8	Intron 2		30037	tttttttttttttttttttt	C/T	tcagtttttttttttttttt		
i-ADORA1-9	Intron 2		30138	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs7555556	
i-ADORA1-10	Intron 2		34431	ccaggccaaatgtttttt	A/C	tttttttttttttttttttt		
i-ADORA1-11	Coding region	5	306	tttttttttttttttttttt	T/G	tttttttttttttttttttt		
i-ADORA1-12	Intron 5		145	tttttttttttttttttttt	T/C	tttttttttttttttttttt		
i-ADORA1-13	Intron 5		508	tttttttttttttttttttt	A/G	tttttttttttttttttttt	rs2228079	
i-ADORA1-14	Intron 5		567	tttttttttttttttttttt	A/G	tttttttttttttttttttt		
i-ADORA1-15	Intron 5		2547	tttttttttttttttttttt	A/G	tttttttttttttttttttt		
i-ADORA1-16	Intron 5		2719	tttttttttttttttttttt	G/C	tttttttttttttttttttt		
i-ADORA1-17	Intron 5		2763	tttttttttttttttttttt	G/A	tttttttttttttttttttt		
i-ADORA1-18	Intron 5		2922	tttttttttttttttttttt	T/A	tttttttttttttttttttt		
i-ADORA1-19	Intron 5		11491	tttttttttttttttttttt	T/A	tttttttttttttttttttt	rs1494485	
i-ADORA1-20	Intron 5		11942	tttttttttttttttttttt	C/T	tttttttttttttttttttt		
i-ADORA1-21	Intron 5		15950	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs3753476	
i-ADORA1-22	Intron 5		16109	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs3753475	
i-ADORA1-23	Intron 5		21833	tttttttttttttttttttt	G/T	tttttttttttttttttttt	rs1845466	
i-ADORA1-24	Intron 5		22340	tttttttttttttttttttt	G/A	tttttttttttttttttttt	rs3766558	
i-ADORA1-25	Intron 5		23766	tttttttttttttttttttt	G/C	tttttttttttttttttttt	rs3766557	
i-ADORA1-26	Intron 5		24059	tttttttttttttttttttt	C/A	tttttttttttttttttttt		
i-ADORA1-27	Intron 5		24806	tttttttttttttttttttt	G/A	tttttttttttttttttttt		
i-ADORA1-28	Intron 5		24870	tttttttttttttttttttt	C/G	tttttttttttttttttttt		
i-ADORA1-29	Intron 5		24948	tttttttttttttttttttt	T/C	tttttttttttttttttttt		
i-ADORA1-30	Intron 5		32975	tttttttttttttttttttt	G/A	tttttttttttttttttttt	rs6677137	
i-ADORA1-31	Intron 5		33223	tttttttttttttttttttt	T/C	tttttttttttttttttttt	rs3753473	
i-ADORA1-32	Intron 5		33471	tttttttttttttttttttt	T/C	tttttttttttttttttttt	rs3753472	
i-ADORA1-33	Intron 5		33734	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs3766556	
i-ADORA1-34	Intron 5		33997	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs3766555	
i-ADORA1-35	3' UTR	6	1278	tttttttttttttttttttt	C/A	tttttttttttttttttttt	rs6427994	
i-ADORA1-36	3' UTR	6	1405	tttttttttttttttttttt	C/T	tttttttttttttttttttt		
i-ADORA1-37	3' UTR	6	1627	tttttttttttttttttttt	G/T	tttttttttttttttttttt		
i-ADORA1-38	3' Flanking region		384	tttttttttttttttttttt	C/T	tttttttttttttttttttt	rs1042295	
i-ADORA1-39	3' Flanking region		451	tttttttttttttttttttt	T/A	tttttttttttttttttttt		
i-ADORA1-40	3' Flanking region		1772	tttttttttttttttttttt	C/T	tttttttttttttttttttt		
i-ADORA1-41	Intron 5		18885-15886	tttttttttttttttttttt	CA/ins	tttttttttttttttttttt		
i-ADORA1-42	Intron 5		33829-35830	tttttttttttttttttttt	T/ins	tttttttttttttttttttt		
i-ADORA1-43	3' UTR	6	1795	tttttttttttttttttttt	C/ins	tttttttttttttttttttt		
i-ADORA1-44	3' Flanking region		350-351	tttttttttttttttttttt	CT/ins	tttttttttttttttttttt		
i-ADORA1-45	3' Flanking region		1234-1255	tttttttttttttttttttt	CT/ins	tttttttttttttttttttt		

Adrenergic, alpha-1A-, receptor i-ADRA1A-1	5' Flanking region	-1554	ccgggaccgaagccgggcc	G/A	rs1075764
i-ADRA1A-2	5' Flanking region	-1385	tccaccaatccccatcccc	G/A	rs3808585
i-ADRA1A-3	5' Flanking region	-1136	gtatccctccggtagtttgc	C/T	rs737045
i-ADRA1A-4	5' Flanking region	-993	cgttggaaaggatcccttgtca	G/A	rs486179
i-ADRA1A-5	5' Flanking region	-877	tggaacgacctggggggcgtt	A/G	rs573542
i-ADRA1A-6	5' Flanking region	-743	ttagcgtlgtcgccgtcccg	A/G	rs574584
i-ADRA1A-7	5' Flanking region	-108	ttaggttaactcgggcccg	G/A	rs1383914
i-ADRA1A-8	5' UTR	1	gggggggggggggggggggg	C/A	rs3824220
i-ADRA1A-9	Intron 1	-50	cttcgttttttttttttttttttt	G/T	rs528257
i-ADRA1A-10	Intron 1	52	tttttttttttttttttttttttt	T/A	rs573514
i-ADRA1A-11	Intron 1	307	tttttttttttttttttttttttt	T/A	rs538378
i-ADRA1A-12	Intron 1	322	tttttttttttttttttttttttt	T/A	rs489790
i-ADRA1A-13	Intron 1	370	tttttttttttttttttttttttt	T/C	rs336401
i-ADRA1A-14	Intron 1	4850	tttttttttttttttttttttttt	A/C	
i-ADRA1A-15	Intron 1	4885	tttttttttttttttttttttttt	C/T	
i-ADRA1A-16	Intron 1	4978	tttttttttttttttttttttttt	C/T	
i-ADRA1A-17	Intron 1	5128	tttttttttttttttttttttttt	C/T	
i-ADRA1A-18	Intron 1	5395	tttttttttttttttttttttttt	A/G	
i-ADRA1A-19	Intron 1	57161	tttttttttttttttttttttttt	C/T	
i-ADRA1A-20	Intron 1	-6406	tttttttttttttttttttttttt	C/T	
i-ADRA1A-21	Intron 1	-5614	tttttttttttttttttttttttt	C/T	
i-ADRA1A-22	Coding region	1039	tttttttttttttttttttttttt	T/C	
i-ADRA1A-23	Intron 2	549	tttttttttttttttttttttttt	G/C	
i-ADRA1A-24	Intron 2	1241	tttttttttttttttttttttttt	T/C	
i-ADRA1A-25	3' Flanking region	126	tttttttttttttttttttttttt	A/T	
i-ADRA1A-26	3' Flanking region	557	tttttttttttttttttttttttt	T/C	
i-ADRA1A-27	3' Flanking region	-479 to -478	tttttttttttttttttttttttt	T/ins	rs4732639
i-ADRA1A-28	3' Flanking region	-76 to -75	tttttttttttttttttttttttt	ACCTGTAGCGC-TGGCTACCCAA/ins	
i-ADRA1A-29	5' Flanking region	-75 to -72	tttttttttttttttttttttttt	GATG/del	
i-ADRA1A-30	Intron 1	-3335 to -334	(ACCTGTAGCGCTG-CGCTACCCAA/ins)	T/ins	rs1048101
i-ADRA1A-31	Intron 2	-2933 to -2934	tttttttttttttttttttttttt	A/ins	rs3739216
i-ADRA1A-32	Intron 2	4318-4319	tttttttttttttttttttttttt	T/del	rs4236679
i-ADRA1A-33	3' UTR	3	tttttttttttttttttttttttt	G/del	
i-ADRA1A-34	3' Flanking region	1567	tttttttttttttttttttttttt		
Adrenergic, alpha-2A-, receptor i-ADRA2A-1	5' Flanking region	2321	tttttttttttttttttttttttt		
i-ADRA2A-2	5' Flanking region	-1083	tttttttttttttttttttttttt	C/T	
i-ADRA2A-3	5' UTR	-125	tttttttttttttttttttttttt	T/A	rs521674
i-ADRA2A-4	5' UTR	1	tttttttttttttttttttttttt	G/T	rs1800763
i-ADRA2A-5	5' UTR	1	tttttttttttttttttttttttt	C/T	rs7089069
i-ADRA2A-6	5' UTR	1	tttttttttttttttttttttttt	G/C	rs1800544
i-ADRA2A-7	Coding region	-727	tttttttttttttttttttttttt	C/G	rs2484516
i-ADRA2A-8	3' UTR	1	tttttttttttttttttttttttt	C/A	rs1800038
i-ADRA2A-9	3' UTR	1	tttttttttttttttttttttttt	C/A	
i-ADRA2A-10	3' UTR	1	tttttttttttttttttttttttt	A/G	Arg365Arg
i-ADRA2A-11	3' UTR	1	tttttttttttttttttttttttt	C/A	rs553668
i-ADRA2A-12	3' Flanking region	1	tttttttttttttttttttttttt	G/A	rs3750625
		1569	tttttttttttttttttttttttt	A/G	rs1122605

Table 2 (Continued)

ID	Location	Exon	Position ^a	5' Flanking sequence ^b	Variation ^c	3' Flanking sequence ^b	Substitution	Identity to dbSNP/ previous report
Adrenergic, alpha-2B-, receptor								
i-ADRA2B-1	5' Flanking region		-1661	gtggcgctggaaataagaggc	C/A	tggctcgaggccgggttat		
i-ADRA2B-2	5' Flanking region		-1447	tttcaacttcgttccccaaaa	G/A	ggccttcgttgttgatgtggg	rs31111873	
i-ADRA2B-3	5' Flanking region		-98	ccaggcccgtccggcc	G/C	gaggcgctggccgttct		
i-ADRA2B-4	Coding region	1	36	ccctactccggccggcc	A/G	ggcccatgtggccggccat	rs2229169	
i-ADRA2B-5	Coding region	1	1173	tttcacgttccggccatgg	A/C	gttcatggccgaaggactg	rs4907299	
i-ADRA2B-6	3' UTR	1	1767	tttttttttttttttttttt	C/A	acaataggaaacggggccatc	rs3813662	
i-ADRA2B-7	3' UTR	1	2194	aaatctttttttttttttttt	T/G	agagaaccaaaatgtatt	Small et al. (2001)	
i-ADRA2B-8 ^d	Coding region	1	903-911	AGAGGAGGGA/del		ggaggaggaaatggaaatgtgg		
i-ADRA2B-9	3' UTR	1	3223-3224	gtgggtttttttttttttttt	T/ins	aaactcttggatctttttttttttt		
Arginine vasopressin receptor 1B								
i-AVPR1B-1	5' Flanking region		-388	acggccatccggctggcgg	A/G	ggccgcgcacacccgcaca		
i-AVPR1B-2	5' UTR	1	-356	ccagaaaatgtttggaaaaaa	A/T	gaattttgggggttggatgtttttt		
i-AVPR1B-3	Coding region	1	571	tttttttttttttttttttttttt	G/C	gttcccttggggccacgg		
i-AVPR1B-4	Coding region	1	821	tttttttttttttttttttttttt	G/A	ggccatggccatgtttttttttttttt		
i-AVPR1B-5	Intron 1	25	25	tttttttttttttttttttttttt	G/T	tgtttttttttttttttttttttttttt		
i-AVPR1B-6	Intron 1	1721	1721	tttttttttttttttttttttttt	G/C	tggttttttttttttttttttttttttt		
i-AVPR1B-7	Intron 1	2475	2475	ttttttttttttttttttttttttt	C/T	ttttttttttttttttttttttttt		
i-AVPR1B-8	Intron 1	2847	2847	ttttttttttttttttttttttttt	T/C	ttttttttttttttttttttttttt		
i-AVPR1B-9	Intron 1	4769	4769	ttttttttttttttttttttttttt	T/C	ttttttttttttttttttttttttt		
i-AVPR1B-10	Intron 1	4966	4966	ttttttttttttttttttttttttt	T/C	ttttttttttttttttttttttttt		
i-AVPR1B-11	Intron 1	4987	4987	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-12	Intron 1	5156	5156	ttttttttttttttttttttttttt	G/C	ttttttttttttttttttttttttt		
i-AVPR1B-13	Coding region	2	1091	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-14	Coding region	2	1119	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-15	3' UTR	2	1284	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-16	3' UTR	2	1285	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-17	3' UTR	2	1336	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-18	3' UTR	2	1393	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-19	3' UTR	2	1398	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-20	3' UTR	2	1563	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-21	3' Flanking region	2	2101	ttttttttttttttttttttttttt	A/G	ttttttttttttttttttttttttt		
i-AVPR1B-22	3' Flanking region	2	2145	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-23	3' Flanking region	2	2303	ttttttttttttttttttttttttt	C/G	ttttttttttttttttttttttttt		
i-AVPR1B-24	3' Flanking region	2	2393	ttttttttttttttttttttttttt	C/G	ttttttttttttttttttttttttt		
i-AVPR1B-25	3' Flanking region	2	2415	ttttttttttttttttttttttttt	C/G	ttttttttttttttttttttttttt		
i-AVPR1B-26	3' Flanking region	2	2595	ttttttttttttttttttttttttt	C/T	ttttttttttttttttttttttttt		
i-AVPR1B-27	3' Flanking region	2	2650	ttttttttttttttttttttttttt	C/T	ttttttttttttttttttttttttt		
i-AVPR1B-28	3' Flanking region	2	2717	ttttttttttttttttttttttttt	C/T	ttttttttttttttttttttttttt		
i-AVPR1B-29	3' Flanking region	2	2762	ttttttttttttttttttttttttt	G/C	ttttttttttttttttttttttttt		
i-AVPR1B-30	3' Flanking region	2	2966	ttttttttttttttttttttttttt	T/C	ttttttttttttttttttttttttt		
i-AVPR1B-31	3' Flanking region	2	2997	ttttttttttttttttttttttttt	G/T	ttttttttttttttttttttttttt		
i-AVPR1B-32	3' Flanking region	2	3024	ttttttttttttttttttttttttt	G/A	ttttttttttttttttttttttttt		
i-AVPR1B-33	3' Flanking region	2	3037	ttttttttttttttttttttttttt	G/T	ttttttttttttttttttttttttt		
i-AVPR1B-34	3' Flanking region	2	3078	ttttttttttttttttttttttttt	A/T	ttttttttttttttttttttttttt		
i-AVPR1B-35	3' Flanking region	2	3111	ttttttttttttttttttttttttt	T/A	ttttttttttttttttttttttttt		
i-AVPR1B-36	Intron 1	4643	4643	ttttttttttttttttttttttttt	T/del	(GTT)8-9		
i-AVPR1B-37	3' UTR	2	1744-1769					

Table 2 (Continued)

ID	Location	Exon	Position ^a	5' Flanking sequence ^b	Variation ^c	3' Flanking sequence ^b	Substitution	Identity to dbSNP/ previous report
i-MC3R-4	Coding region	1	17	ttaaatgagatccaaaga	C/A	gtatctggaggagatttg	Thy1lys	rs3746619
i-MC3R-5	Coding region	1	241	aggccatcaacccggag	G/A	ttttccgcgttcggccat	V _{al} 81Ile	rs3827103
i-MC3R-6	3' Flanking region		1006	gttgtacttgcgtggacc	C/T	ttttttttttttttttttttt		rs2870730
i-MC3R-7	3' Flanking region		1211	ggccactatgtctgcatt	G/C	tttttttttttttttttttt		rs6014650
i-MC3R-8	3' Flanking region		1504	atttttttttttttttttttt	C/G	tttttttttttttttttttt		
Melanocortin 4 receptor								
i-MC4R-1	5' Flanking region		-1207	gttttttttttttttttttttt	C/T	tttttttttttttttttttt		rs8087522
i-MC4R-2	5' Flanking region		-1005	ggatatttttttttttttttt	C/T	tttttttttttttttttttt		Lubrano-Berthelier et al. (2003)
i-MC4R-3	5' Flanking region		-896	cttttttttttttttttttttt	A/C	tttttttttttttttttttt		
i-MC4R-4	5' Flanking region		-178	tttttttttttttttttttttt				
i-MC4R-5	Coding region	1	307	caaatggatcaaaaaccatt	G/A	tttttttttttttttttttt	V _{al} 103Ile	rs2229616
i-MC4R-6	3' Flanking region		1151	gttttttttttttttttttttt	C/G			
i-MC4R-7	5' Flanking region		-1157 to -1156	tttttttttttttttttttttt	A/ins			
Oxytocin receptor								
i-OXTR-1	5' Flanking region		-353	tttttttttttttttttttttt	C/A	tttttttttttttttttttt		rs1465386
i-OXTR-2	5' UTR	1	-346	tttttttttttttttttttttt	C/T	tttttttttttttttttttt		rs3806675
i-OXTR-3 ^e	5' UTR	1	-550	tttttttttttttttttttttt	T/C	tttttttttttttttttttt		rs2301260
i-OXTR-4	5' UTR	1	-485	tttttttttttttttttttttt	G/A	tttttttttttttttttttt		rs968389
i-OXTR-5	Inton 1	21	tttttttttttttttttttttt	T/C	tttttttttttttttttttt		rs2301261	
i-OXTR-6	Inton 1	397	tttttttttttttttttttttt	G/T	tttttttttttttttttttt			
i-OXTR-7	Inton 1	606	tttttttttttttttttttttt	A/G	tttttttttttttttttttt		rs237915	
i-OXTR-8	Inton 2	132	tttttttttttttttttttttt	G/T	tttttttttttttttttttt		rs237913	
i-OXTR-9	5' UTR	3	-135	tttttttttttttttttttttt	T/C	tttttttttttttttttttt		rs237911
i-OXTR-10	Coding region	3	171	tttttttttttttttttttttt	C/T	tttttttttttttttttttt		rs2228485
i-OXTR-11	Inton 3	667	tttttttttttttttttttttt	A/G	tttttttttttttttttttt		rs237897	
i-OXTR-12	Inton 3	811	tttttttttttttttttttttt	G/T	tttttttttttttttttttt		rs2268496	
i-OXTR-13	Inton 3	1088	tttttttttttttttttttttt	T/C	tttttttttttttttttttt			
i-OXTR-14	Inton 3	2638	tttttttttttttttttttttt	A/T	tttttttttttttttttttt		rs237893	
i-OXTR-15	Inton 3	3002	tttttttttttttttttttttt	T/C	tttttttttttttttttttt			
i-OXTR-16	Inton 3	3350	tttttttttttttttttttttt	C/T	tttttttttttttttttttt		rs151463	
i-OXTR-17	Inton 3	3396	tttttttttttttttttttttt	A/G	tttttttttttttttttttt		rs2268494	
i-OXTR-18	Inton 3	3586	tttttttttttttttttttttt	A/C	tttttttttttttttttttt		rs2268491	
i-OXTR-19	Inton 3	4581	tttttttttttttttttttttt	T/C	tttttttttttttttttttt			
i-OXTR-20	Inton 3	5157	tttttttttttttttttttttt	C/T	tttttttttttttttttttt			
i-OXTR-21	Inton 3	6906	tttttttttttttttttttttt	A/T	tttttttttttttttttttt			
i-OXTR-22	Inton 3	8554	tttttttttttttttttttttt	G/A	tttttttttttttttttttt			
i-OXTR-23	Inton 3	9108	tttttttttttttttttttttt	T/G	tttttttttttttttttttt			
i-OXTR-24	Coding region	4	1126	tttttttttttttttttttttt	C/G	tttttttttttttttttttt		rs53576
i-OXTR-25	3' UTR	4	1288	tttttttttttttttttttttt	C/A	tttttttttttttttttttt		
i-OXTR-26	3' UTR	4	2817	tttttttttttttttttttttt	A/C	tttttttttttttttttttt		
i-OXTR-27	3' Flanking region		866	tttttttttttttttttttttt				
Somatostatin receptor 1								
i-SSTR1-1	Inton 1		226	tttttttttttttttttttttt	G/A	tttttttttttttttttttt		rs4073844
i-SSTR1-2	Inton 2		98	tttttttttttttttttttttt	A/G	tttttttttttttttttttt		rs4394988
i-SSTR1-3	5' UTR	3	-239	tttttttttttttttttttttt	G/A	tttttttttttttttttttt		
i-SSTR1-4	5' UTR	3	-103	tttttttttttttttttttttt	T/G	tttttttttttttttttttt		

i-SSTR1-5	Coding region	3	879	aacgttgttgcgagcaga accctgeacatctatccit	C/T	Val2293Val	rs2228497
i-SSTR1-6	3' UTR	3	1486	gacccttcatttttc ccctactcgccgtttcca	T/C		
i-SSTR1-7	3' UTR	3	2054	ccctgggggggggggg ccctctatctttttttttt	A/G		
i-SSTR1-8	3' UTR	3	2146	tcttttttttttttttttt tttttttttttttttttttt	G/A		
i-SSTR1-9	3' UTR	3	2519	gttttttttttttttttt tttttttttttttttttttt	G/A		rs1135473
i-SSTR1-10	3' UTR	3	2632	tttttttttttttttttt tttttttttttttttttttt	G/C		rs1135474
i-SSTR1-11	3' UTR	3	2675	tttttttttttttttttt tttttttttttttttttttt	C/T		rs4143959
i-SSTR1-12	3' Flanking region	425	993	tttttttttttttttttt tttttttttttttttttttt	G/A		rs4640088
i-SSTR1-13	3' Flanking region	993	-823	tttttttttttttttttt tttttttttttttttttttt	C/T		
i-SSTR1-14	5' Flanking region	-297 to -288		tttttttttttttttttt tttttttttttttttttttt	A/del		
i-SSTR1-15	5' Flanking region			tttttttttttttttttt tttttttttttttttttttt	TTCTTCCAC/del		
Somatostatin receptor 3	5' Flanking region			tttttttttttttttttt tttttttttttttttttttt	C/T		
i-SSTR3-1	5' Flanking region		-1463	tttttttttttttttttt tttttttttttttttttttt	G/A		
i-SSTR3-2	5' Flanking region		-867	tttttttttttttttttt tttttttttttttttttttt	G/C		
i-SSTR3-3	5' Flanking region		-725	tttttttttttttttttt tttttttttttttttttttt	G/T		rs6000607
i-SSTR3-4	5' Flanking region		-108	tttttttttttttttttt tttttttttttttttttttt	T/C		rs69264
i-SSTR3-5	Coding region	1	99	tttttttttttttttttt tttttttttttttttttttt	G/A		rs86583
i-SSTR3-6	Coding region	1	453	tttttttttttttttttt tttttttttttttttttttt	A/G		Ala99Ala
i-SSTR3-7	Coding region	1	792	tttttttttttttttttt tttttttttttttttttttt	A/G		Ser151Ser
i-SSTR3-8	Coding region	1	822	tttttttttttttttttt tttttttttttttttttttt	C/T		Ala264Ala
i-SSTR3-9	3' Flanking region		1280	tttttttttttttttttt tttttttttttttttttttt	C/T		Tyr274Tyr
Tumor necrosis factor receptor superfamily, member 1A				tttttttttttttttttt tttttttttttttttttttt			rs7576556
i-TNFRSFIA-1	5' Flanking region		-1931	tttttttttttttttttt tttttttttttttttttttt	C/T		
i-TNFRSFIA-2	5' Flanking region		-1786	tttttttttttttttttt tttttttttttttttttttt	G/A		
i-TNFRSFIA-3	Coding region	1	36	tttttttttttttttttt tttttttttttttttttttt	A/G		Pro12Pro
i-TNFRSFIA-4	Intron 1		364	tttttttttttttttttt tttttttttttttttttttt	T/C		rs767455
i-TNFRSFIA-5	Intron 1		3420	tttttttttttttttttt tttttttttttttttttttt	C/T		rs4149623
i-TNFRSFIA-6	Intron 1		3505	tttttttttttttttttt tttttttttttttttttttt	G/A		rs4149577
i-TNFRSFIA-7	Intron 1		3952	tttttttttttttttttt tttttttttttttttttttt	T/C		rs4149578
i-TNFRSFIA-8	Intron 1		3957	tttttttttttttttttt tttttttttttttttttttt	A/G		rs4149580
i-TNFRSFIA-9	Intron 1		4165	tttttttttttttttttt tttttttttttttttttttt	C/T		rs4149581
i-TNFRSFIA-10	Intron 1		4960	tttttttttttttttttt tttttttttttttttttttt	T/G		rs887477
i-TNFRSFIA-11	Intron 1		5613	tttttttttttttttttt tttttttttttttttttttt	C/G		rs2284344
i-TNFRSFIA-12	Intron 1		5979	tttttttttttttttttt tttttttttttttttttttt	C/G		
i-TNFRSFIA-13	Coding region	3	269	tttttttttttttttttt tttttttttttttttttttt	C/T		
i-TNFRSFIA-14	Intron 4		187	tttttttttttttttttt tttttttttttttttttttt	T/C		
i-TNFRSFIA-15	Intron 6		10	tttttttttttttttttt tttttttttttttttttttt	A/G		rs1800692
i-TNFRSFIA-16	Intron 7		294	tttttttttttttttttt tttttttttttttttttttt	T/C		rs1800693
i-TNFRSFIA-17	5' Flanking region		-1707 to -1702	tttttttttttttttttt tttttttttttttttttttt	CTCCCT/del		
i-TNFRSFIA-18	5' Flanking region		-1663 to -1662	tttttttttttttttttt tttttttttttttttttttt	AGAAATTCTAGC-		
				tttttttttttttttttt tttttttttttttttttttt	TGCCTGCAATTCT-		
				tttttttttttttttttt tttttttttttttttttttt	AGCAGCCCCA/ins		
i-TNFRSFIA-19	Intron 1		4002-4003	tttttttttttttttttt tttttttttttttttttttt	T/ins		
i-TNFRSFIA-20	3' UTR	10	1741-1745	tttttttttttttttttt tttttttttttttttttttt	TTTTT/del		
i-TNFRSFIA-21	3' Flanking region		768-769	tttttttttttttttttt tttttttttttttttttttt	CC/ins		
G protein-coupled receptor 1				tttttttttttttttttt tttttttttttttttttttt			
i-GPR1-1	Coding region	1	39	tttttttttttttttttt tttttttttttttttttttt	A/G		
i-GPR1-2	Coding region	1	193	tttttttttttttttttt tttttttttttttttttttt	T/C		
i-GPR1-3	Coding region	1	531	tttttttttttttttttt tttttttttttttttttttt	C/T		
i-GPR1-4	Coding region	1	706	tttttttttttttttttt tttttttttttttttttttt	C/T		
i-GPR1-5	Coding region	1	919	tttttttttttttttttt tttttttttttttttttttt	A/G		
				tttttttttttttttttt tttttttttttttttttttt	Ile307Val		rs3732083

Table 2 (Continued)

ID	Location	Exon	Position ^a	5' Flanking sequence ^b	Variation ^c	3' Flanking sequence ^b	Substitution	Identity to dbSNP/ previous report
G protein-coupled receptor 2								
i-GPR2-1	5' Flanking region		-786	gttcctggcccccgcgtt	G/C	tctctatcccttc		
i-GPR2-2	3' Flanking region		1294	gcggccccggggaggcccg	G/A	ccggccccggggccctgc		rs3809757
G protein-coupled receptor 3								
i-GPR3-1	5' Flanking region		-125	ttggatataggcatggac	T/C	ctatcggatccctggagg		rs2504786
i-GPR3-2	3' Flanking region		724	ggtttttttttttaaga	A/C	gccccacatggccacaa		
i-GPR3-3	3' Flanking region		229-238	ctacccaaaaatgtccaca	CCCCAGCTGG/del	gttcaattccaatgtcg		
G protein-coupled receptor 4								
i-GPR4-1	5' UTR	1	-527	ggccggactccaccaat	T/C	gcctgaacctttccaaacact		rs3745818
i-GPR4-2	5' UTR	1	-277	gttggaaacactgtaccata	C/T	ataaacctcgtaaaaaacct		
i-GPR4-3	5' UTR	1	-127	ccatccatcttcctgttata	C/T	cacatccacatgtttcc		rs3745819
i-GPR4-4	5' UTR	1	-60	ggcccatggccatccgttc	C/T	cttgtggcccaatgcggcccg		
i-GPR4-5	Coding region	1	1044	tggggggccactccggcc	C/T	caggggggccatggccgt		
i-GPR4-6	3' UTR	1	1720	tcgtggatccggggaaatgt	G/A	gaagggtttggggaaaatgt	Ser348Ser	
i-GPR4-7	3' UTR	1	1914	cgtccggggggggatgtcc	A/G	ccaaacatggataaaaatgc		rs1045217
i-GPR4-8	3' UTR	1	1681	gaagggttagttttttttttt	T/del			
G protein-coupled receptor 10								
i-GPR10-1	5' Flanking region		-1701	gtttttaaaggggggcccta	T/C	aaagggcccttcctccgg		rs4440948
i-GPR10-2	5' Flanking region		-517	ctatgttttttttttttttttt	C/T	atggcggatggcgttcacc		
i-GPR10-3	5' Flanking region		-462	atggggatgttttttttttttt	T/C	ggggccgttttttttttttttt		rs1538265
i-GPR10-4	5' Flanking region		-62	gggggggggggggggggg	A/G	gagggttttttttttttttttt		rs3740551
i-GPR10-5	Coding region	1	615	tatccatgttttttttttttt	G/T	cacatgttttttttttttttt	Pro203Pro	

^aNucleotide numbering is according to the mutation nomenclature (den Dunnin and Antonarakis 2000)^bBoth 5' and 3' flanking sequences to each variation are denoted by *small letters*^s^cVariation is shown by a *capital letter*^dNucleotide numbering of 903-910(AGAGGAGGA/del) in exon 1 of the *ADRA2B* gene was according to a cDNA sequence NM_000682.2^eNucleotide numbering of a -550C/T SNP was according to a cDNA sequence NM_000916.2

for A/C, and 6% for A/T; transitions occurred 2.1 times more frequently than transversions. By comparing SNPs detected in this study with previous reports from elsewhere (Sturm et al. 2001; Lubrano-Berthelier et al. 2003; Schalin-Jantti et al. 2003) or with the dbSNP database at NCBI, we were able to consider 132 of the 300 SNPs (44%) to be novel as of the end of December 2003.

We also identified two novel nonsense mutations in the Japanese healthy donors. One is a 322C → T (Arg108Stop) in *ADORA3* belonging to adenosine receptor gene family. The other is a 706C → T (Arg236Stop) in an anonymous G protein-coupled receptor 1 gene. Both SNPs, each of which was identified in a single individual among the 48 volunteers tested, would be predicted to lack nearly half of the C-terminal part of each gene product. However, since these mutations were found in the healthy donors, we have no information regarding its potential effects on the carrier's susceptibility to any diseases or drug responses. In all cases, more detailed genetic and functional studies will be necessary to clarify a relationship between these mutations and functional properties of these receptors.

Altogether, we have collected a total of 333 genetic variations, including 300 SNPs and 33 genetic variations of other types, among the 23 genes encoding G-protein coupled receptors by screening 96 Japanese chromosomes. We hope our SNP catalog can contribute to further investigations for identifying genes associated with drug efficacy and/or adverse drug reactions and for designing personalized medical care.

References

- Dunnen JT den, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 15:7–12
- Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T (2002) Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. *J Hum Genet* 47:605–610
- Howard AD, McAllister G, Feighner SD, Liu Q, Nargund RP, Van der Ploeg LH, Patchett AA (2001) Orphan G-protein-coupled receptors and natural ligand discovery. *Trends Pharmacol Sci* 22:132–140
- Iida A, Nakamura Y (2003) Japanese efforts in pharmacogenomics. *Curr Pharmacogenom* 1:203–215
- Iida A, Sekine A, Saito S, Kitamura Y, Kitamoto T, Osawa S, Mishima C, Nakamura Y (2001a) Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. *J Hum Genet* 46:225–240
- Iida A, Saito S, Sekine A, Kitamoto T, Kitamura Y, Mishima C, Osawa S, Kondo K, Harigae S, Nakamura Y (2001b) Catalog of 434 single-nucleotide polymorphisms (SNPs) in genes of the alcohol dehydrogenase, glutathione S-transferase, and nicotinamide adenine dinucleotide, reduced (NADH) ubiquinone oxidoreductase families. *J Hum Genet* 46:385–407
- Iida A, Saito S, Sekine A, Kitamura Y, Kondo K, Mishima C, Osawa S, Harigae S, Nakamura Y (2001c) High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1(*ABCA1*) gene. *J Hum Genet* 46:522–528
- Iida A, Saito S, Sekine A, Harigae S, Osawa S, Mishima C, Kondo K, Kitamura Y, Nakamura Y (2001d) Catalog of 46 single-nucleotide polymorphisms (SNPs) in the microsomal glutathione S-transferase 1 (*MGST1*) gene. *J Hum Genet* 46:590–594
- Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, Nakamura Y (2001e) Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. *J Hum Genet* 46:668–683
- Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002a) Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (*CHST1*) and carbohydrate sulfotransferase 3 (*CHST3*) genes. *J Hum Genet* 47:14–19
- Iida A, Saito S, Sekine A, Kondo K, Mishima C, Kitamura Y, Harigae S, Osawa S, Nakamura Y (2002b) Thirteen single-nucleotide polymorphisms (SNPs) in the alcohol dehydrogenase 4 (*ADH4*) gene locus. *J Hum Genet* 47:74–76
- Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002c) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: *ABCA4*, *ABC47*, *ABC48*, *ABCD1*, *ABCD3*, *ABCD4*, *ABCE1*, *ABCf1*, *ABCg1*, *ABCg2*, *ABCg4*, *ABCg5*, and *ABCg8*. *J Hum Genet* 47:285–310
- Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002d) Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: *UGT2A1*, *UGT2B15*, and *UGT8*. *J Hum Genet* 47:505–510
- Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2003) Catalog of 668 SNPs detected among 31 genes encoding potential drug targets on the cell surface. *J Hum Genet* 48:23–46
- Lubrano-Berthelier C, Cavazos M, Le Stunff C, Haas K, Shapiro A, Zhang S, Bougnères P, Vaisse C (2003) The human MC4R promoter: characterization and role in obesity. *Diabetes* 52:2996–3000
- Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol Sci* 22:368–376
- Nickerson DA, Tobe VO, Taylor SL (1997) PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. *Nucl Acids Res* 25:2745–2751
- Rana BK, Shiina T, Insel PA (2001) Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. *Annu Rev Pharmacol Toxicol* 41:593–624
- Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y (2001a) Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (*EPHX1* and *EPHX2*) in the Japanese population. *J Hum Genet* 46:325–329
- Saito S, Iida A, Sekine A, Miura Y, Sakamoto T, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y (2001b) Identification of 197 genetic variations in six human methyltransferase genes in the Japanese population. *J Hum Genet* 46:529–537
- Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y (2002a) Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (*ABCB/MDR/TAP*), in the Japanese population. *J Hum Genet* 47:38–50
- Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y (2002b) Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (*ABCC/MRP/CFTR*). *J Hum Genet* 47:147–171
- Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, Ohno M, Nakamura Y (2002c) 906 variations among 27 genes encoding cytochrome P450 (CYP) enzymes and aldehyde dehydrogenases (ALDHs) in the Japanese population. *J Hum Genet* 47:419–444

- Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y (2002d) Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. *J Hum Genet* 47:576–584
- Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, Nakamura Y (2003a) Catalog of 680 variations among eight cytochrome p450 (*CYP*) genes, nine esterase genes, and two other genes in the Japanese population. *J Hum Genet* 48:249–270
- Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, Nakamura Y (2003b) Catalog of 178 variations in the Japanese population among eight human genes encoding G protein-coupled receptors (GPCRs). *J Hum Genet* 48:461–468
- Schalin-Jantti C, Valli-Jaakola K, Oksanen L, Martelin E, Laitinen K, Krusius T, Mustajoki P, Heikinheimo M, Kontula K (2003) Melanocortin-3-receptor gene variants in morbid obesity. *Int J Obes Relat Metab Disord* 27:70–74
- Sekine A, Saito S, Iida A, Mitsunobu Y, Higuchi S, Harigae S, Nakamura Y (2001) Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes *NAT1*, *NAT2*, *AANAT*, *ARD1* and *L1CAM* in the Japanese population. *J Hum Genet* 46:314–319
- Small KM, Brown KM, Forbes SL, Liggett SB (2001) Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. *J Biol Chem* 276:4917–4922
- Sturm RA, Teasdale RD, Box NF (2001) Human pigmentation genes: identification, structure and consequences of polymorphic variation. *Gene* 277:49–62